Authors: Barry Y. Emara, Rasha Stino
Author Disclosure Block: B.Y. Emara: All other investments; Imprimis/Frayne Pharmacy. R. Stino: None.

Abstract Body:

Purpose: To assess efficacy of transzonular injection of 0.2 ml triamcinolone acetonide (TA) and moxifloxacin hydrochloride in prevention of infection and inflammation post cataract surgery in first 1166 eyes. 

Study Design: Retrospective chart review 

Methods: Charts of 666 patients (1166 eyes) receiving transzonular injection of triamcinolone acetonide (TA) and moxifloxacin hydrochloride at conclusion of cataract surgery by single surgeon (B.Y.E.) from February 2016 to September 2018 were reviewed. Outcome measures included additional postoperative steroid drops required post dropless cataract surgery and endophthalmitis. 

Results: Of 884 eyes of 501 patients undergoing dropless conventional cataract surgery (383 bilateral (766 eyes) 118 unilateral (118 eyes)), 72 eyes (8.1%) required additional steroid drops. Of 282 eyes of 165 patients undergoing dropless femtosecond laser-assisted cataract surgery (FLACS) (117 bilateral (234 eyes) 48 unilateral (48 eyes)), 34 eyes (11.9%) required additional steroid drops. Of 1166 total eyes of 666 patients undergoing dropless cataract surgery, 106 eyes (9.1%) required additional steroid drops. There were no cases of endophthalmitis noted. 

Conclusions: Transzonular injection of 0.2 ml triamcinolone acetonide (TA) and moxifloxacin hydrochloride was efficacious in the prevention of infection and inflammation post cataract surgery in the first 1166 eyes, with less than 10% of eyes requiring additional steroid drops and no cases of endophthalmitis observed.